In addition, if the heightened anxiety symptoms are the result of insufficient serotonergic activation during development, it may be speculated that treatment with a 5-HT1A agonist at a young age may exert some measure of protection against the emergence of later anxiety symptoms. The gene discussed is HTR1A; the disease is Anxiety.